Tag: platform

Strategic rollout across major e-commerce platforms in the U.S. and UK reinforces APR's expanding global beauty device footprint.Sequential launches planned across TikTok Shop and...

Collaboration leverages Gemini Enterprise to onboard engineers up to three times fasterAMSTERDAM, June 11, 2026 /PRNewswire/ -- Google Cloud today announced a collaboration with Randstad...

Nokia introduces agentic AI framework in Network Services Platform to enable trust-based AI operations for IP networks

SINGAPORE, June 11, 2026 /PRNewswire/ -- DKSH entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and potential patient access to a...

Almost half of UK consumers want a Summer Black Friday Promotion, new Independent research shows*Black Friday offers, but hotter: Joybuy's Summer Black Friday offers...

HAIKOU, China, June 11, 2026 /PRNewswire/ -- A news report from chinadaily.com.cn Hainan province is doubling down on its digital economy, leveraging free trade port...

From Pearl Studio, the Studio Behind Kung Fu Panda 3, the Mythological Comedy Marks the Next Major Chinese Animated Release as Chinese Animation Continues...

HAIKOU, China, June 11, 2026 /PRNewswire/ -- A news report from chinadaily.com.cn ...

From living longer to living free, people across Asia prioritize health and financial self-sufficiency to pursue independence and avoid burdening loved onesHONG KONG, June...

From living longer to living free, people across Asia prioritize health and financial self-sufficiency to pursue independence and avoid burdening loved onesHONG KONG, June...

CARPL.ai and Enlitic partner to accelerate imaging AI validation through structured, searchable imaging data for healthcare organizations.

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

Establishes a regulatory-compliant, state-of-the-art Genome-Edited (GE) Crop Field Testing Facility to accelerate global commercialization.Enables comprehensive field evaluation of a diversified crop portfolio, including drought...